Previous close | 10.68 |
Open | 10.70 |
Bid | 11.40 x 900 |
Ask | 11.41 x 800 |
Day's range | 10.55 - 10.84 |
52-week range | 7.72 - 27.48 |
Volume | |
Avg. volume | 1,116,216 |
Market cap | 1.425B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the
SAN FRANCISCO, February 23, 2024--Vir Biotechnology to participate in upcoming March investor healthcare conferences
SAN FRANCISCO, February 22, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.